# Cellular Biomedicine Group, Inc.

Cellular Biomedicine Group, Inc. is a company headquartered in Rockville, MD, United States.

## Company overview

- **Legal name:** Cellular Biomedicine Group, Inc.
- **Former names in filing history:** EastBridge Investment Group Corp (2006-10-31 to 2013-02-22)
- **Classification:** Company
- **Industry (SIC):** 2836 — Biological Products, (No Diagnostic Substances)
- **Headquarters:** Rockville, MD, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0001378624

## About

Cellular Biomedicine Group, Inc. is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0001378624, and its reported industry is Biological Products, (No Diagnostic Substances). In 10-K filed on 2020-02-28, it reported annual revenue of USD 339,920; net income of USD -49,984,054; total assets of USD 97,324,300 for the fiscal period ended 2019-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2019 (period ended 2019-12-31)

- **Revenue:** $339,920 (USD 339,920)
- **Net income:** -$50.0M (USD -49,984,054)
- **Total assets:** $97.3M (USD 97,324,300)
- **Cash and equivalents:** $15.4M (USD 15,443,649)
- **Operating cash flow:** -$39.6M (USD -39,649,983)
- **Later filings:** Cash and equivalents: shown as originally filed; later filings report different values for the same periods.

### FY2018 (period ended 2018-12-31)

- **Revenue:** $224,403 (USD 224,403)
- **Net income:** -$38.9M (USD -38,945,492)
- **Total assets:** $91.6M (USD 91,643,146)
- **Operating cash flow:** -$25.1M (USD -25,112,999)
- **Later filings:** Total assets: shown as originally filed; later filings report different values for the same periods.

### FY2017 (period ended 2017-12-31)

- **Revenue:** $336,817 (USD 336,817)
- **Net income:** -$25.5M (USD -25,490,310)
- **Total assets:** $61.2M (USD 61,162,296)
- **Operating cash flow:** -$18.6M (USD -18,593,392)

### FY2016 (period ended 2016-12-31)

- **Revenue:** $627,930 (USD 627,930)
- **Net income:** -$28.2M (USD -28,208,376)
- **Total assets:** $68.6M (USD 68,628,467)
- **Operating cash flow:** -$15.9M (USD -15,867,735)

## Recent SEC filings

- Form 8-K — filed 2021-02-19 — period 2021-02-19 — CURRENT REPORT
- Form 8-K — filed 2021-02-08 — period 2021-02-08 — FORM 8-K
- Form DEF 14A — filed 2021-02-01 — period 2021-02-01 — PRIMARY DOCUMENT
- Form 8-K — filed 2021-02-01 — period 2021-02-01 — CURRENT REPORT
- Form 8-K — filed 2021-01-29 — period 2021-01-29 — 8-K
- Form 8-K — filed 2020-12-04 — period 2020-12-04 — CURRENT REPORT
- Form 10-Q — filed 2020-11-09 — period 2020-09-30 — QUARTERLY REPORT
- Form 8-K — filed 2020-10-26 — period 2020-10-23 — CURRENT REPORT
- Form 8-K — filed 2020-08-28 — period 2020-08-28 — PRIMARY DOCUMENT
- Form SC 13D — filed 2020-08-14 — SC 13D
- Form 10-Q — filed 2020-08-12 — period 2020-06-30 — QUARTERLY REPORT
- Form 8-K — filed 2020-08-12 — period 2020-08-11 — 8-K

---

Updated: 2026-10-23T20:08:00Z

Canonical page: https://altss.com/profile/cellular-biomedicine-group-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology